AZN Stock Price Today (October 2026) — AstraZeneca PLC Analysis & Key Metrics 2026-10-08
AstraZeneca PLC (AZN) is trading at $158.78, down 0.84% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $212.17 (33.6% upside).
- Volatility is low (18.31% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.40% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
AZN Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
AstraZeneca PLC - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $273.63B
P/E Ratio
Forward P/E: 14.27
Revenue Growth
Year over Year
Analyst Target
+33.6% upside potential
Key Investor Questions About AZN
What investors need to know before buying
Based on current market data, AZN presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 42.10)
- Fundamentals say: Looking solid (debt and growth supportive)
AZN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AZN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $32.35B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AZN stock traded between $153.41 and $212.71 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 18.31% annualized volatility and β=0.34, the stock exhibits low sensitivity to market moves—making AZN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market?
AstraZeneca PLC (NYSE:AZN) announced on September 11, 2026, that its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib failed to meet its primary endpoint of progression-free survival (PFS) in patients with upfront first-line ER-positive, HER2-negative advanced breast cancer. While the regimen demonstrated numerical improvement over standard anastrozole plus palbociclib, it did not […]
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
AZN's Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.
AstraZeneca (LSE:AZN) Gets EU Support For Two Key Drugs
AstraZeneca (LSE:AZN) received positive opinions from the EMA's CHMP for Enhertu and Klygefa in the European Union. The CHMP backed Enhertu as an adjuvant treatment option for early-stage HER2-positive breast cancer with high risk of recurrence. The committee also supported Klygefa as an add-on therapy for generalised myasthenia gravis, targeting patients with a rare autoimmune condition. These fresh CHMP views on Enhertu and Klygefa sit alongside a wider set of AstraZeneca developments...
AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’
Britain’s biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research.
AstraZeneca (LSE:AZN) Stock May Be 48% Undervalued On Enhertu Trial Progress
AstraZeneca has ridden a strong five year share price run and a steady stream of oncology and respiratory trial updates, which raises a simple question for investors who care about valuation. Is the current price around £125.60 broadly in line with what the company’s cash flows can support, or has sentiment run ahead of the underlying economics? Over the past 5 years, AstraZeneca has delivered a share price gain of 62.7%, which puts a lot of weight on whether its future cash generation can...
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo’s Enhertu has been cleared for use by England’s National Health Service (NHS) for patients with HER2-low metastatic breast cancer, reversing an earlier NICE decision that rejected funding on cost-effectiveness grounds. NICE’s revised recommendation follows changes to drug valuation methods and a U.S.-UK agreement aimed at aligning medicine prices. Around […]
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note
In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
Guardant Health has also earned a spot on the Investor's Business Daily Leaderboard. Earlier this month, the FDA approved Guardant360 CDx as a companion diagnostic for Etcamah from AstraZeneca in advanced or metastatic breast cancer. Guardant360 CDx is the first FDA-approved liquid biopsy CDx for longitudinal testing in breast cancer.
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
AstraZeneca's Klygefa wins a positive EU recommendation for AChR-positive gMG, backed by phase III data and a convenient once-weekly treatment option.
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies
AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.
Explore More Analysis for AZN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 30, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about AstraZeneca PLC
AstraZeneca PLC (AZN) is currently trading at $158.78. The RSI (14-day) is at 42.1, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $212.17 implies 33.6% upside from current levels. Volatility is low at 18.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AstraZeneca PLC (AZN): The trailing P/E ratio is 24.48, which is in line with broader market averages. The forward P/E is 14.27, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.42, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 5.05. Price-to-Sales is 4.14. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering AZN, the consensus price target is $212.17. This represents a 33.6% upside from the current price of $158.78. The range spans from a low target of $184.00 to a high target of $240.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AstraZeneca PLC (AZN) pays a dividend with a current yield of approximately 2.02%. The annualized dividend rate is $3.23 per share. The payout ratio is 47.4%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Aug 7, 2026.
Key risks for AstraZeneca PLC (AZN) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AstraZeneca PLC's (AZN) current debt and financial health profile: Total debt stands at $32.35B. The debt-to-equity ratio is 0.64x, which is moderate and generally manageable for most companies. The current ratio is 0.89, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.66. The company holds $4.97B in cash and equivalents. Free cash flow is positive at $4.91B, providing a cushion for debt servicing and shareholder returns.